Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR)

Historical Holders from Q2 2020 to Q3 2025

Symbol
LRMR on Nasdaq
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
85,635,017
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
85,510,151
Holdings value
$274,838,015
% of all portfolios
0.002%
Number of holders
136
Number of buys
88
Number of sells
-35
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Flynn James E 35.81% $106,722,810 30,667,474 Deerfield Management Company, L.P. 31 Jul 2025
MILLENNIUM MANAGEMENT LLC 5.8% +3.3% $16,043,858 +$4,532,710 4,966,831 +39.4% Millennium Management LLC 30 Sep 2025
Opaleye Management Inc. 4.8% -22.8% $15,412,500 +$590,966 4,110,000 +4% Opaleye Management, Inc. 29 Aug 2025
BlackRock, Inc. 4.8% -6% $7,175,619 -$433,939 3,079,665 -5.7% BlackRock, Inc. 31 Mar 2025
GOLDMAN SACHS GROUP INC 4.1% $6,058,491 2,600,210 THE GOLDMAN SACHS GROUP, INC. 31 Mar 2025

Institutional Holders of Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 85,510,151 $274,838,015 +$75,245,053 $3.23 136
2025 Q2 62,321,311 $180,120,860 +$7,437,034 $2.89 116
2025 Q1 60,827,153 $131,864,050 -$12,271,759 $2.15 101
2024 Q4 63,434,614 $245,492,888 -$5,894,960 $3.87 115
2024 Q3 64,329,070 $421,287,622 -$5,929,383 $6.55 122
2024 Q2 65,308,461 $473,379,696 +$12,179,883 $7.25 105
2024 Q1 63,594,662 $482,627,362 +$182,781,336 $7.59 102
2023 Q4 39,456,509 $179,551,948 +$15,220,703 $4.55 69
2023 Q3 38,745,394 $153,032,401 -$3,458,223 $3.95 63
2023 Q2 39,027,692 $120,194,716 -$3,770,373 $3.13 65
2023 Q1 38,462,442 $174,244,129 +$1,086,191 $4.53 68
2022 Q4 38,766,976 $160,093,910 +$976,279 $4.13 47
2022 Q3 38,715,175 $123,902,000 +$77,822,908 $3.2 52
2022 Q2 14,391,311 $28,222,000 -$2,241,518 $1.96 34
2022 Q1 15,257,103 $61,778,000 -$2,584,495 $4.05 40
2021 Q4 14,567,301 $157,170,000 -$456,088 $10.79 47
2021 Q3 14,519,322 $167,488,004 +$199,976 $11.53 50
2021 Q2 14,543,964 $142,828,000 -$4,477,645 $9.82 42
2021 Q1 14,110,404 $206,147,000 -$8,290,625 $14.61 53
2020 Q4 14,252,270 $305,135,000 +$10,378,818 $21.41 42
2020 Q3 13,625,016 $206,745,000 +$10,359,632 $15.17 37
2020 Q2 12,953,044 $166,142,000 +$166,142,000 $12.85 34